Safety and efficacy of fimasartan in patients with arterial hypertension (Safe-KanArb study): an open-label observational study

Jeong Bae Park, Ki-Chul Sung, Seok-Min Kang, Eun Joo Cho, Jeong Bae Park, Ki-Chul Sung, Seok-Min Kang, Eun Joo Cho

Abstract

Background: Angiotensin II receptor blockers (ARBs) play a key role in hypertension therapy. Recently, fimasartan, the ninth ARB, was developed, but its safety and efficacy have not been well established.

Objective: The objective of this study was to determine whether age, sex, concomitant disease, and current antihypertensive medications affect the safety and efficacy of fimasartan in patients with arterial hypertension.

Methods: This was a large-scale, open-label observational study to determine the safety and efficacy of fimasartan in patients with hypertension. Patients who were treated for more than 2 months with fimasartan (60 or 120 mg, once daily) were recruited, and the data were systematically collected using electronic case report forms. Written informed consent forms were obtained from all patients.

Results: A total of 14,151 patients (50.7 % males; mean age 59 ± 12 years) were evaluated, of whom 37.9 % were never treated with fimasartan, 53.5 % were switched to fimasartan, and 8.5 % had fimasartan added to their treatment. Overall, fimasartan reduced systolic blood pressure (SBP) from 145.4 ± 18.1 to 126.8 ± 12.6 mmHg and diastolic blood pressure (DBP) from 88.7 ± 11.8 to 79.0 ± 8.7 mmHg (all p < 0.001). The pulse rate decreased from 74.4 ± 10.3 to 71.9 ± 9.2 beats/min in comparison with before treatment (p < 0.001). The reductions were similar between sexes, age groups, and patients with and without co-morbidities, and were not dependent on prior or concomitant treatment with other antihypertensive drugs. Adverse events were reported in 3.31 % (treatment-emergent) and 2.35 % (drug-related) of patients; there were no dose differences for adverse events. The most frequent adverse events were dizziness (1.55 %) and headache (0.52 %); other adverse events were rare. The responder rate (DBP to <90 mmHg or a reduction of ≥10 mmHg) and the goal rate (combined SBP/DBP <140/90 mmHg) were 85.0 and 75.6 %, respectively. Global drug compliance was rated as excellent, very good, good, and poor in 68.1, 26.9, 3.4, and 1.7 % of patients, respectively.

Conclusion: The safety, efficacy, and compliance of fimasartan were found to be excellent in a large patient population that included patients potentially at higher risk for adverse events.

Figures

Fig. 1
Fig. 1
Changes in systolic (SBP) and diastolic (DBP) blood pressure in all patients treated with 60 and 120 mg of fimasartan

References

    1. Wassmann S, Nickenig G. The role of the AT1 receptor in the cardiovascular continuum. Eur Heart J. 2004;6(Suppl H):H3–H9. doi: 10.1093/eurheartj/6.suppl_h.h3.
    1. Aulakh GK, Sodhi RK, Singh M. An update on non-peptide angiotensin receptor antagonists and related RAAS modulators. Life Sci. 2007;81(8):615–639. doi: 10.1016/j.lfs.2007.06.007.
    1. Gavras H, Flessas A, Ryan TJ, et al. Angiotensin II inhibition: treatment of congestive cardiac failure in a high-renin hypertension. JAMA. 1977;238:880–892. doi: 10.1001/jama.1977.03280090044020.
    1. Choi DJ, Han S, Jeon ES, et al. Characteristics, outcomes and predictors of long-term mortality for patients hospitalized for acute heart failure: a report from the Korean heart failure registry. Korean Circ J. 2011;41(7):363–371. doi: 10.4070/kcj.2011.41.7.363.
    1. Sawada T, Yamada H, Dahlöf B, et al. on Kyoto Heart Study Group. Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: Kyoto Heart Study. Eur Heart J. 2009;30(20):2461–9.
    1. Mochizuki S, Dahlöf B, Shimizu M, et al. on Jikei Heart Study Group. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet. 2007;369(9571):1431–9.
    1. Mancia G, De Backer G, Dominiczak A, et al. Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) J Hypertens. 2007;25:1105–1187. doi: 10.1097/HJH.0b013e3281fc975a.
    1. Ogihara T, Kikuchi K, Matsuoka H, et al. Japanese Society of Hypertension committee. The Japanese society of hypertension guidelines for the management of hypertension (JSH 2009). Hypertens Res. 2009;32(1):3–107.
    1. The Seventh Report of Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289:2560–72.
    1. Wexler RR, Greenlee WJ, Irvin JD, et al. Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy. J Med Chem. 1996;39:625–656. doi: 10.1021/jm9504722.
    1. Zannad F, Fay R. Blood pressure-lowering efficacy of olmesartan relative to other angiotensin II receptor antagonists: an overview of randomized controlled studies. Fundam Clin Pharmacol. 2007;21(2):181–190. doi: 10.1111/j.1472-8206.2007.00464.x.
    1. White WB, Weber MA, Sica D, et al. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension. 2011;57(3):413–420. doi: 10.1161/HYPERTENSIONAHA.110.163402.
    1. Nagel JM, Tietz AB, Göke B, et al. The effect of telmisartan on glucose and lipid metabolism in nondiabetic, insulin-resistant subjects. Metabolism. 2006;55(9):1149–1154. doi: 10.1016/j.metabol.2006.04.011.
    1. Sica DA, Schoolwerth AC. Part 1. Uric acid and losartan. Curr Opin Nephrol Hypertens. 2002;11(5):475–482. doi: 10.1097/00041552-200209000-00001.
    1. Yi S, Kim TE, Yoon SH, et al. Pharmacokinetic interaction of fimasartan, a new angiotensin II receptor antagonist, with amlodipine in healthy volunteers. J Cardiovasc Pharmacol. 2011;57:682–689. doi: 10.1097/FJC.0b013e31821795d0.
    1. Kim TW, Yoo BW, Lee JK, Kim JH, Lee KT, Chi YH, Lee JY. Synthesis and antihypertensive activity of pyrimidin-4(3H)-one derivatives as losartan analogue for new angiotensin II receptor type 1 (AT1) antagonists. Bioorg Med Chem Lett. 2012;22(4):1649–1654. doi: 10.1016/j.bmcl.2011.12.116.
    1. Lee SE, Kim YJ, Lee HY, et al. Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): A 12-week, Phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension. Clin Ther. 2012;34(3):552–568. doi: 10.1016/j.clinthera.2012.01.024.
    1. Basile J. Blood pressure responder rates versus goal rates: which metric matters? Ther Adv Cardiovasc Dis. 2009;3(2):157–174. doi: 10.1177/1753944708101552.
    1. Yusuf S, Teo K, Anderson C, on Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomized controlled trial. Lancet. 2008;372:1174–1183. doi: 10.1016/S0140-6736(08)61193-9.
    1. McIntyre M, Coffe SE, Michalok RA, et al. Losartan, an orally active angiotensin (AT1) receptor antagonist: a review of its efficacy and safety in essential hypertension. Pharmacol Ther. 1997;74(2):181–194. doi: 10.1016/S0163-7258(97)82002-5.
    1. McClellan JK, Goa KL. Candesartan cilexetil: a review of its use in essential hypertensions. Drugs. 1998;56(5):847–869. doi: 10.2165/00003495-199856050-00013.
    1. Gillis JC, Merkham A. Irbesartan: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension. Drugs. 1997;54(6):885–902. doi: 10.2165/00003495-199754060-00007.
    1. Sica D, White WB, Weber MA, et al. Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich) 2011;13:467–472. doi: 10.1111/j.1751-7176.2011.00482.x.
    1. Haymore BR, Yoon J, Mikita CP, et al. Risk of angioedema with angiotensin receptor blockers in patients with prior angioedema associated with angiotensin-converting enzyme inhibitors: a metaanalysis. Ann Allergy Asthma Immunol. 2008;101:495–499. doi: 10.1016/S1081-1206(10)60288-8.
    1. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547–1559. doi: 10.1056/NEJMoa0801317.
    1. Sica DA, Black HR. Current concepts of pharmacotherapy in hypertension: ACE inhibitor-related angioedema: can angiotensin-receptor blockers be safely used? J Clin Hypertens (Greenwich) 2002;4:375–380. doi: 10.1111/j.1524-6175.2002.01509.x.
    1. Oparil S, Williams D, Chrysant SG, et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens. 2001;3:283–291. doi: 10.1111/j.1524-6175.2001.01136.x.
    1. Neutel JM, Smith DHG. Evaluation of angiotensin II receptor blockers for 24-hour blood pressure control: Meta-analysis of a clinical database. J Clin Hypertens. 2003;1:58–63.
    1. Center for Drug Evaluation and Research Medical Review(s). NDA: 200796 Azilsartan medoxomil (Edarbi) for hypertension [online]. .
    1. Blankestijn PJ, Rupp H. Clinical profile of eprosartan: a different angiotensin II receptor blocker. Cardiovasc Hematol Agents Med Chem. 2008;6(4):253–257. doi: 10.2174/187152508785909500.
    1. Wogen J, Kreilick CA, Livornese RC, et al. Patient adherence with amlodipine, lisinopril, or valsartan therapy in a usual-care setting. J Manag Care Pharm. 2003;9(5):424–429.
    1. Vegter S, Nguyen NH, Visser ST, et al. Compliance, persistence, and switching patterns for ACE inhibitors and ARBs. Am J Manag Care. 2011;17(9):609–616.
    1. Enlund H. Measuring patient compliance in antihypertensive therapy—some methodological aspects. J Clin Hosp Pharm. 1982;7(1):43–51.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다